Enfermedad metabólica ósea postrasplante

  1. Federico Hawkins Carranza 1
  2. María Begoña López Álvarez
  3. María Ángeles Valero Samuy
  4. Sonsoles Guadalix Iglesias
  5. María Soledad Librizzi
  6. Guillermo Martínez Díaz Guerra
  1. 1 Real Academia de Medicina; Instituto de Investigación i+12, Hospital Univ. 12 de Octubre; Facultad de Medicina UCM
Revista:
Anales de la Real Academia Nacional de Medicina

ISSN: 0034-0634

Ano de publicación: 2019

Número: 136

Páxinas: 249-255

Tipo: Artigo

DOI: 10.32440/AR.2019.136.03.REV03 DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Anales de la Real Academia Nacional de Medicina

Resumo

Osteoporosis can become a severe potential complication of organ transplantation, (OTx) that can lead to a greater risk for fractures and lower quality of life. The purpose has been to review state of this subject, taking in account our experience, in relation to the pathophysiology and therapy of postransplanted patients. After OTx, glucocorticoids are the more deleterious agents on bone remodeling, which is particularly important in the first six months postransplantation, with a tendency in some to some recovery after, but that persist in others. Cyclosporine and other immunosuppressors associated to steroids, can contribute to the deterioration of bone remodeling. Treatment is being subject to different studies and clinical trials, being bisphosphonates the agents more widely used. Alendronate, risedronate, and zolendronic acid, have a similar efficiency, but bone adverse effects should be observed during their administration. Finally, calcium and vitamin D, administration is recommended, given the frequent deficit of this vitamin, increased by steroids.

Referencias bibliográficas

  • Lofdahl E, Radegran G. Osteoporosisfollowing heart transplantation and immunosuppressive therapy. Transplant Rev 107; 201: 232-239.
  • Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am 2007; 36(4): 937-963.
  • Kulak CA, Borba VZ, Kulak Júnior J, Campos DJ, Shane E. Posttransplantation osteoporosis. Arq Bras Endocrinol Metabol 2010; 54(2): 143-149.
  • Monegal A, Navasa M, Guanabens N, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001; 12(6): 484-492.
  • Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12(9): 1390-1402.
  • Hamburg SM, Piers DA, van den Berg AP, Slooff MJ, Haagsma EB. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11(7): 600-606.
  • Vedi S, Greer S, Skingle SJ, et al. Mechanism of bone loss after liver transplantation: a histomorphometric analysis. J Bone Miner Res 1999; 14(2):281-287.
  • Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001; 69(6): 321-326.
  • Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: longterm follow-up and predictive factors. Liver Transpl 2006; 12(9):1390-1402.
  • Floreani A, Mega A, Tizian L et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int 2001; 12(9): 749-754.
  • García-Delgado I, Prieto S, Gil-Fraquas L, Robles E, Rufilanchas JJ, Hawkins F. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 1997; 60(2): 155-159.
  • Valero MA, Loinaz C, Larrodera L, León M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995; 57(1): 15-19.
  • Hawkins FG, León M, López MB, et al. Bone loss and turnover in patients with liver transplantation. Hepatogastroenterology 1994; 41(2): 158-161.
  • López MB, González Pinto I, Hawkins F, et al. Effect of liver transplantation and immunosuppressive treatment on bone mineral density. Transplant Proc 1992; 24(6): 3044-3046.
  • Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998; 104(5): 459-469.
  • Wang H, Jiang W, Zhou Z, et al. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report. Hepatobiliary Surg Nutr 2013; 2(4):188-197.
  • Dolgos S, Hartmann A, Isaksen GA, et al. Osteoporosis is a prevalent finding in patients with solid organ failure awaiting transplantation - a population based study. Clin Transplant 2010; 24(5): E145-152.
  • Danovitch GM, Cohen DJ, Weir MR, et al. Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant 2005; 5(4 Pt 2): 904-915.
  • Bianda T, Linka A, Junga G, et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 2000; 67(2): 116-121.
  • Negri AL, Perrone S, Gallo R, Bogado CE, Zanchetta JR. Osteoporosis following heart transplantation. Transplant Proc 1996; 28(6): 3321-3324.
  • Thiébaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26(7): 549-555.
  • Eshane E, Epstein S. Transplantation osteoporosis. Transplant Rev 2001: 15: 11-13.
  • Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 1997; 82(5): 1497-1506.
  • Pisani B, Mullen GM. Prevention of osteoporosis in cardiac transplant recipients. Curr Opin Cardiol 2002; 17(2): 160-164.
  • Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90(4): 2456-2465.
  • Chauhan V, Ranganna KM, Chauhan N, Vaid M, Kelepouris E. Bone disease in organ transplant patients: pathogenesis and management. Postgrad Med 2012; 124(3): 80-90.
  • Kulak CA, Borba VZ, Kulak Júnior J, Shane E. Transplantation osteoporosis. Arq Bras Endocrinol Metabol 2006; 50(4): 783-792.
  • Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin NorthAcad Sci U S A 2005; 102(47): 17130-17135.
  • Sun L, Blair HC, Peng Y, et al. Calcineurin regulates bone formation by the osteoblast Proc Natl Acad Sci U S A 2005; 102(47): 17130-17135
  • Sun L, Peng Y, Zaidi N, et al. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts.Am J Physiol Renal Physiol 2007; 292(1): F285-291.
  • Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994 27; 57(8): 1231-1237.
  • Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996; 11(1): 1-7.
  • Bowman AR, Sass DA, et al. The role of testosterone in cyclosporine-induced osteopenia. J Bone Miner Res 1997; 12(4): 607-615.
  • Martínez Díaz-Guerra G, Gómez R, Jódar E, Loinaz C, Moreno E, Hawkins F. Long-term follow-up of bone mass after orthotopic liver transplantation: Effect of steroid withdrawal from the immunosuppressive regimen. Osteoporos Int 2002; 13(2): 147-150.
  • Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997 15; 63(3): 380-386.
  • Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med 1993; 94(3): 257-264.
  • Anijar JR, Szejnfeld VL, Almeida DR, Fernandes AR, Ferraz MB. Reduced bone mineral density in men after heart transplantation. Braz J Med Biol Res 1999; 32(4): 413-420.
  • Stempfle HU, Werner C, Siebert U, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002 27; 73(4): 547- 552.
  • Goffin E, Devogelaer JP, Lalaoui A, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002; 15(2-3): 73-80.
  • Bryer HP, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995; 10(1): 132-138.
  • Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoidinduced osteoporosis. Biochem Biophys Res Commun 2009 6; 379(2): 261-266.
  • Giannini S, Nobile M, Ciuffreda M, et al. Longterm persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 2000; 11(5): 417-424.
  • Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y. Osteoporosis after organ transplantation. Lancet 2001 19; 357(9268): 1623.
  • Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Liver Transpl 2004; 10(5): 638-647.
  • Gilfraguas L, Guadalix S, Martínez G, et al. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin and calcium plusvitamin D3. Prog Transplant 2012; 22(3): 237-243.
  • Nel JD, Epstein S. Metabolica bone disease in the post-transplant population. Med Clin Nam 2016; 100: 569-586.
  • Guadalix S, Martínez-Díaz Guerra G, Lora D, et al. Effect of early risedronate treatment onbone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. Transplant Int 2011; 24 (7): 657-665.
  • Librizzi MS, Guadalix S, Martínez-Díaz Guerra G, et al. Trabecular bone score in patients with liver transplants after1 year of risedronate treatment. Transpl Int 2016; 29(3): 331-337. Am 2007; 36(4): 937-963. 29. Sun L, Blair HC, Peng Y, et al. Calcineurin regulates bone formation by the osteoblast Proc Natl
Fonte de datos: Dialnet